1 unchanged sentence
Rule 10b5-1 Trading Plans
−Removed: During the quarter ended September 30, 2024, none of our directors or executive officers adopted, modified or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K).
+Added: During the quarter ended March 31, 2025, none of our directors or executive officers adopted, modified or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K).
+Added: Amendment to Building D Lease Agreement, dated April 10, 2024, between Myriad Genetics, Inc.
+Added: and ATP SLC D, LLC (incorporated by reference to Exhibit 10.4.2 to the Company’s Annual Report on Form 10-K, File No.
+Added: 000-26642, filed with the SEC on February 28, 2025).
+Added: Lease Agreement, dated December 1, 2012, by and between Assurex Health, Inc.
+Added: and the City of Mason, Ohio (incorporated by reference to Exhibit 10.6.1 to the Company’s Annual Report on Form 10-K, File No.
+Added: 000-26642, filed with the SEC on February 28, 2025).
+Added: Fifth Addendum to Lease Agreement, dated February 20, 2025, between Assurex Health, Inc.
+Added: and the City of Mason, Ohio (incorporated by reference to Exhibit 10.6.2 to the Company’s Annual Report on Form 10-K, File No.
+Added: 0-26642, filed with the SEC on February 28, 2025).
+Added: Amended and Restated Employment Agreement, dated February 24, 2025, between Myriad Genetics, Inc.
+Added: and Samraat S.
+Added: Raha (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8 -K, File No.
+Added: 00 0-26642, filed with the SEC on February 2 4 , 2025).
+Added: Chief Executive Officer Severance and Change of Control Agreement, dated February 24, 2025, by and between Myriad Genetics, Inc.
+Added: and Samraat S.
+Added: Raha (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, File No.
+Added: 00 0-26642, filed with the SEC on February 24, 2025 ).
+Added: Employment Agreement, dated February 24, 2025, by and between the Company and Mark S.
+Added: Verratti (incorporated by reference to Exhibit 10.
+Added: 3 to the Company’s Current Report on Form 8-K, File No.
+Added: 00 0-26642, filed with the SEC on February 24, 2025 ).
+Added: Severance and Change of Control Agreement, dated February 24, 2025, by and between the Company and Mark S.
+Added: Verratti (incorporated by reference to Exhibit 10.
+Added: 4 to the Company’s Current Report on Form 8-K, File No.
+Added: 00 0-26642, filed with the SEC on February 24, 2025 ).
+Added: Consulting Agreement, dated February 24, 2025, by and between the Company and Paul J.
+Added: Diaz (incorporated by reference to Exhibit 10.
+Added: 5 to the Company’s Current Report on Form 8-K, File No.
+Added: 00 0-26642, filed with the SEC on February 24, 2025 ).
+Added: Restricted Stock Unit Agreement , dated May 1, 2025, by and between t he Company and Brian Donnelly .
+Added: Performance-Based Restricted Stock Unit Agreement, dated May 1, 2025, by and between the Company and Brian Donnelly .
31.1 Certification of Chief Executive Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.
7 unchanged sentences
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document.
−Removed: 104 The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 has been formatted in Inline XBRL.
+Added: 104 The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 has been formatted in Inline XBRL.
+Added: + Management contract or compensatory plan or arrangement.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
MYRIAD GENETICS, INC.
−Removed: November 8, 2024 By:
+Added: May 7, 2025 By:
+Added: /s/ Samraat S.
President and Chief Executive Officer
(Principal executive officer)
−Removed: November 8, 2024 By:
+Added: May 7, 2025 By:
Chief Financial Officer
(Principal financial officer)
−Removed: November 8, 2024 By:
+Added: May 7, 2025 By:
/s/ Natalie Munk
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.